Teva Pharmaceutical Industries Limited (TEVA)
| Market Cap | 42.46B +105.1% |
| Revenue (ttm) | 17.32B +4.1% |
| Net Income | 706.00M |
| EPS | 0.60 |
| Shares Out | 1.17B |
| PE Ratio | 60.56 |
| Forward PE | 12.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,140,895 |
| Open | 37.37 |
| Previous Close | 37.62 |
| Day's Range | 36.37 - 37.42 |
| 52-Week Range | 17.89 - 38.37 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 41.40 (+13.61%) |
| Earnings Date | Jul 29, 2026 |
About TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for TEVA stock is "Buy." The 12-month stock price target is $41.4, which is an increase of 13.61% from the latest price.
News
Teva unit bids to acquire neuroscience product from BioXcel Therapeutics
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries (TEVA) announced it has made a bid to acquire an innovative neuroscience product from BioXcel Therapeutics (BTAI...
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disor...
BioXcel Therapeutics enters asset sale agreement with Teva
BioXcel Therapeutics (BTAI) announced that it has entered into an asset sale agreement with Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries (TEVA), for substant...
Aurinia settles patent litigation with Teva
Aurinia Pharmaceuticals (AUPH) announced that it and its subsidiary, Aurinia Pharma U.S., Inc., have entered into a settlement agreement with Teva Pharmaceuticals Inc. (TEVA) to resolve patent infring...
Aurinia Settles Patent Litigation with Teva
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.
TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer
Shares in Teva Pharmaceutical Industries ($TEVA) were healthier today after a potential 50-year-long breakthrough treatment for Tourette syndrome moved a step closer. Ecopipam Application Accepted The...
Teva announces FDA acceptance of ecopipam NDA
Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva, announced that the FDA accepted the new drug application, or NDA, for ecopipam, with a targeted action date late in the first…
U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U...
Teva price target raised to $42 from $40 at Barclays
Barclays raised the firm’s price target on Teva (TEVA) to $42 from $40 and keeps an Overweight rating on the shares post the Q2 report. The firm sees potential for…
Teva price target raised to $42 from $40 at Barclays
Barclays raised the firm’s price target on Teva (TEVA) to $42 from $40 and keeps an Overweight rating on the shares post the Q2 report. The firm sees potential for…
Humana agrees not to reference Teva's Israel ties at US drug trial
Health insurer Humana has agreed not to refer to drugmaker Teva as an Israeli company at an upcoming U.S. drug price-fixing trial, after the drugmaker said public views on the Gaza war could unfairly...
TEVA Maintained by Barclays -- Price Target Raised to $42.00
TEVA Maintained by Barclays -- Price Target Raised to $42.00
Teva (TEVA) Q2 2026 Earnings Call Transcript
Key innovative brands now generate over $1B quarterly revenue.
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
SUPN vs. TEVA: Which Stock Is the Better Value Option?
Teva seeks to keep Israel ties from jury, cites Gaza war
Teva Pharmaceuticals has asked a U.S. judge to prevent insurer Humana from telling jurors it is an Israeli company at a major drug price-fixing trial, arguing that strong public views over the Gaza ...
Why Teva Pharmaceutical Stock Surged This Week
Teva posted its Q2 results this week, reporting an earnings miss even though sales beat expectations. The company's forward guidance didn't deliver big surprises, but it looked solid enough.
Teva Pharmaceutical Industries Q2 Earnings Call Highlights
Teva Pharmaceutical Industries NYSE: TEVA reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were lar...
TEVA SWOT Analysis: Financial Struggles Amidst Strategic Shifts Revealed in 10-Q Filing
TEVA SWOT Analysis: Financial Struggles Amidst Strategic Shifts Revealed in 10-Q Filing
TEVA Looks 71.0% Overvalued on GF Value⢠as Insider Selling Persists
TEVA Looks 71.0% Overvalued on GF Value⢠as Insider Selling Persists
Is Teva Pharmaceutical Industries Ltd (TEVA) Overvalued After 9.6% Rally? GF Value Says Overvalued
Is Teva Pharmaceutical Industries Ltd (TEVA) Overvalued After 9.6% Rally? GF Value Says Overvalued
Stocks to Watch Recap: Ford, Caterpillar, Teva, Starbucks
Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations
Teva CEO on Q2 earnings: 'Good growth across the whole portfolio'
Richard Francis, President and CEO of Teva Pharmaceuticals, joins 'Squawk on the Street' to discuss Q2 results, drug pipeline, generics business, and more.
Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views
Teva's bullish guidance overshadowed mixed second-quarter results.
Watch CNBC's full interview with Teva Pharmaceuticals CEO Richard Francis
Richard Francis, President and CEO of Teva Pharmaceuticals, joins 'Squawk on the Street' to discuss Q2 results, drug pipeline, generics business and more.